Carlos A. Schuler
Founder at InCarda Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Howard Robin | M | 71 | 17 years | |
| Jennifer Ruddock | F | - | 20 years | |
| Mark Wilson | M | 52 | 22 years | |
| Samantha Miller | F | 59 |
InCarda Therapeutics, Inc.
 InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | 4 years |
| Alan Colowick | M | 61 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | 6 years |
| George Bickerstaff | M | 68 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | 4 years |
| Louis Lange | M | 72 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | - |
| Daniel Welch | M | 66 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | 5 years |
| Johan Rutger Christenson | M | 65 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | - |
| Luiz Belardinelli | M | - |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | 8 years |
| Isaac Cheng | M | 49 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | - |
| Andrew ElBardissi | M | 42 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | - |
| Chet Leach | M | - |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gil Labrucherie | M | 52 | 17 years | |
| Grace Colón | M | 57 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | 10 years |
| Narasimhan Rangachari | M | - |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | - |
| John Nicholson | M | 72 | 12 years | |
| Timothy Harkness | M | 57 | - | |
| Lutz Lingnau | M | 81 | 13 years | |
| Jillian Thomsen | F | 58 | 17 years | |
| Lisa G. Garrett | F | 55 |
ForSight VISION5, Inc.
 ForSight VISION5, Inc. Electronic Equipment/InstrumentsElectronic Technology ForSight VISION5, Inc. develops ocular drug delivery technologies and device solutions for ophthalmic diseases. It engages in the development of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. Its lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The company was founded by Eugene de Juan Jr., J. Andrew Corley and K. Angela Macfarlane in 2010 and is headquartered in Madison, NJ. | - |
| Hector Casab | M | - |
ForSight VISION5, Inc.
ForSight VISION5, Inc. Electronic Equipment/InstrumentsElectronic Technology ForSight VISION5, Inc. develops ocular drug delivery technologies and device solutions for ophthalmic diseases. It engages in the development of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. Its lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The company was founded by Eugene de Juan Jr., J. Andrew Corley and K. Angela Macfarlane in 2010 and is headquartered in Madison, NJ. | 1 years |
| John Stuart Patton | M | 77 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | - |
| Susan S. Wang | F | 73 | 13 years | |
| Robert Lisicki | M | 57 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | 1 years |
| Truc Le | M | 71 | 6 years | |
| Joseph J. Krivulka | M | 73 | 13 years | |
| Carlo J. di Fonzo | M | - | - | |
| Linda A. Adreveno | F | 68 | 5 years | |
| Mohamad Tabrizi | M | - | 10 years | |
| Dorian Hirth | F | - | - | |
| Anil Singhal | M | 72 | 2 years | |
| Edward F. Smith | M | 70 | 2 years | |
| Lorianne K. Masuoka | M | 62 | 3 years | |
| Charles Semba | M | 64 |
ForSight VISION5, Inc.
ForSight VISION5, Inc. Electronic Equipment/InstrumentsElectronic Technology ForSight VISION5, Inc. develops ocular drug delivery technologies and device solutions for ophthalmic diseases. It engages in the development of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. Its lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The company was founded by Eugene de Juan Jr., J. Andrew Corley and K. Angela Macfarlane in 2010 and is headquartered in Madison, NJ. | 2 years |
| Christopher Kurtz | M | 57 | 5 years | |
| Surendra Patel | M | 69 | - | |
| Ittai Harel | M | 56 | 3 years | |
| Louis C. Drapeau | M | 79 | 1 years | |
| Timothy A. Riley | M | - | - | |
| Timothy C. Warner | M | 78 | - | |
| Nevan Elam | M | 56 | 3 years | |
| Juergen A. Martens | M | 68 | 5 years | |
| Melvin Perelman | M | - | - | |
| Norbert W. Bischofberger | M | 68 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | - |
| Ajit S. Gill | M | - | - | |
| Stephen Hurst | M | - | 8 years | |
| Viraj J. Patel | M | 61 | 1 years | |
| Brigid Makes | F | 68 | 7 years | |
| David J. Johnston | M | 61 | 3 years | |
| Mona Chadha | F | 63 | 3 years | |
| Aaron Davidson | M | 55 |
ForSight VISION5, Inc.
ForSight VISION5, Inc. Electronic Equipment/InstrumentsElectronic Technology ForSight VISION5, Inc. develops ocular drug delivery technologies and device solutions for ophthalmic diseases. It engages in the development of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. Its lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The company was founded by Eugene de Juan Jr., J. Andrew Corley and K. Angela Macfarlane in 2010 and is headquartered in Madison, NJ. | 2 years |
| Michael Brown | M | 65 | 7 years | |
| Dorian L. Rinella | F | - | - | |
| Ed Mathers Mathers | M | 64 | 2 years | |
| Truc Le | M | 71 | - | |
| Joseph F. Bohan | M | 66 | 5 years | |
| Ajay Bansal | M | 62 | 3 years | |
| Michael J. Simms | M | 62 | 4 years | |
| Kevin Brodbeck | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 60 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Carlos A. Schuler
- Personal Network
